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A B S T R A C T   
Atrial fibrillation (AF) is associated with an increased risk of stroke, enhanced stroke severity, and other 
comorbidities. However, AF is often asymptomatic, and frequently remains undiagnosed until complications 
occur. Current screening approaches for AF lack either cost-effectiveness or diagnostic sensitivity; thus, there is 
interest in tools that could be used for population screening. An AF risk prediction algorithm, developed using 
machine learning from a UK dataset of 2,994,837 patients, was found to be more effective than existing models at 
identifying patients at risk of AF. Therefore, the aim of the trial is to assess the effectiveness of this risk prediction 
algorithm combined with diagnostic testing for the identification of AF in a real-world primary care setting. 
Eligible participants (aged ≥30 years and without an existing AF diagnosis) registered at participating UK 
general practices will be randomised into intervention and control arms. Intervention arm participants identified 
at highest risk of developing AF (algorithm risk score ≥ 7.4%) will be invited for a 12‑lead electrocardiogram 
(ECG) followed by two-weeks of home-based ECG monitoring with a KardiaMobile device. Control arm partic-
ipants will be used for comparison and will be managed routinely. The primary outcome is the number of AF 
diagnoses in the intervention arm compared with the control arm during the research window. If the trial is 
successful, there is potential for the risk prediction algorithm to be implemented throughout primary care for 
narrowing the population considered at highest risk for AF who could benefit from more intensive screening for 
AF. 
Trial Registration: NCT04045639   
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1. Introduction 
Atrial Fibrillation (AF) – the most common sustained heart 
arrhythmia [1] – is associated with a five-fold increase in stroke risk [2] 
and enhanced stroke severity compared to patients without AF, resulting 
in greater disability and higher mortality [3,4]. As AF can be intermit-
tent and asymptomatic it is challenging to diagnose. Data indicate that 
only 70–85% of patients living with AF have been formally diagnosed 
[5,6]. Early identification of undiagnosed AF and appropriate manage-
ment including anticoagulation therapy is essential to reduce stroke risk 
in patients with AF. 
Multiple screening approaches are available for the identification of 
AF, all with varying cost-effectiveness and diagnostic ability [7]. 
Screening tends to be opportunistic (e.g. screening of patients attending 
their general practitioner (GP) for another reason), targeted (e.g. 
screening of higher-risk patients), or systematic (e.g. screening all pa-
tients aged >65 years), and can include simple pulse checking or more 
resource-intensive electrocardiogram assessment (ECG). European 
guidelines recommend opportunistic screening via pulse taking or ECG 
rhythm strip in patients ≥65 years of age, and only recommend sys-
tematic ECG screening in individuals ≥75 years or those at high risk of 
stroke [7]. Opportunistic screening is recommended because it is more 
likely to be cost-effective than systematic population screening ap-
proaches [7–9]. However, opportunistic screening relies on patients 
visiting their GP for a different reason and pulse checking often lacks 
diagnostic precision [7,10], resulting in many patients with intermittent 
AF having a missed diagnosis, and others undergoing unnecessary 
further testing. 
These limitations, alongside further uncertainties about the benefits 
of screening and the effectiveness of treatment for AF in patients iden-
tified through screening are likely reasons for the absence of a national 
screening programme for AF in the UK [11]. Therefore, given the esti-
mated size of the undiagnosed AF population (approximately 300,000 
individuals in the UK [5,13]), and the absence of cost-effective sys-
tematic screening approaches for AF, there is interest in methods that 
are cost-effective, diagnostically precise, and able to be applied across a 
population to narrow the patient population at highest risk of AF that 
should undergo more intensive screening for AF. 
Existing risk prediction models for AF include the CHARGE-AF [14], 
ARIC [15], Framingham AF [16], and SAAFE [17] models. However, 
some of these depend on ECG-derived data [15,16], include many var-
iables, and are not implemented in clinical practice because none of 
them are automated. 
Previously we reported on the development of an AF risk prediction 
algorithm that utilised machine learning techniques [18]. The algorithm 
was trained and tested based on retrospective data of patients (≥30 
years) listed on the UK Clinical Practice Research Datalink (CPRD) 
GOLD, and validated against existing AF prediction models (CHARGE- 
AF [14], ARIC [15], Framingham AF [16]). Compared with the best- 
performing existing AF model (CHARGE-AF [14]), the machine 
learning algorithm was more effective at identifying patients with AF, 
reducing the number of patients needed to screen to identify one case of 
AF (with 75% sensitivity) from 13 to 9. However, whether this risk 
prediction algorithm when combined with diagnostic testing is accurate 
at identifying undiagnosed AF in a real-world primary care setting is 
currently unknown. Therefore, the Prediction of Undiagnosed atriaL 
fibrillation using a machinE learning AlgorIthm (PULsE-AI) randomised 
controlled trial is designed to assess the real-world ability of the machine 
learning AF risk prediction algorithm coupled with diagnostic testing 
(ECG ± KardiaMobile) for the identification of patients with AF 
compared to routine care. 
2. Study objectives 
The primary objective of the PULsE-AI trial is to assess the effec-
tiveness of an AF risk prediction algorithm and diagnostic testing (ECG 
± KardiaMobile) for the identification of patients with AF in primary 
care, compared to routine care. The primary outcome/endpoint is the 
prevalence of confirmed AF (% with diagnosed AF) during the research 
window in intervention and control arms. The secondary objective is to 
assess the economic impact (healthcare resource utilisation, life years, 
and quality-adjusted life years) of using the AF risk prediction algorithm 
and diagnostic testing (ECG ± KardiaMobile) for the identification of 
patients with AF. 
3. Methods 
3.1. Study design 
The PULsE-AI trial is a prospective, randomised controlled trial 
conducted in the UK primary care setting. Eligible adult patients regis-
tered at participating general practices within the NIHR Clinical 
Research Network: West Midlands will be identified from medical re-
cords and then individually randomised to receive routine care plus the 
intervention/screening strategy (intervention arm) or routine care only 
(control arm). Diagnostic data will be extracted from medical records of 
both intervention and control arm participants at the beginning and end 
of the research window to determine the proportion of patients diag-
nosed with AF throughout the trial in the intervention and control arms. 
The research window is defined as the time between the first 
collection of patient medical records at the beginning of the trial (06 
June 2019) and the last collection following the completion of the 
intervention at the end of the trial. This research window will not be 
fixed but will be sufficient to allow participating practices enough time 
to conduct the intervention. The research window will be consistent 
across sites and trial arms to ensure the same time period for AF diag-
nosis remains the same for all participants. 
This protocol has been designed in accordance with the Standardized 
Protocol Items: Recommendations for Interventional Trials (SPIRIT) 
guidelines and checklist (Supplementary Marerial). A schedule for 
enrolment, intervention and assessment (SPIRIT figure) is outlined in 
Table 1. A CONsolidated Standards of Reporting Trials (CONSORT) di-
agram is shown in Fig. 1. 
3.2. Study population 
Adult patients (≥ 30 years) without a diagnosis of AF prior to 06 June 
2019 will be identified from the medical records of participating general 
practices. Patients aged ≥30 years were included because this age group 
were included in the development of the machine learning risk- 
prediction algorithm. Patients will be eligible for participation in the 
trial if they have a complete set of key clinical measurements (height, 
weight, body mass index (BMI), systolic blood pressure (SBP), and dia-
stolic blood pressure (DBP); i.e. a valid index date) recorded during a 
rolling 12-month window ending at any time during the 11 years prior to 
the start of the research window). All eligible patients will then be 
randomised into intervention and control arms in a 1:1 ratio via simple 
randomisation. Intervention and control group patients with a risk score 
≥ 7.4% will form the primary analysis population, and all randomised 
patients will be included in a sensitivity analysis. Following random-
isation and AF risk score generation, general practitioners (GPs) will 
review the lists of patients randomised to the intervention arm at highest 
risk of AF before letters of invitation are sent, to ensure all patients are 
suitable to participate in the trial. GPs may choose not to invite patients 
based on their clinical judgment (e.g. patients receiving end of life care, 
patients with active cancer, patients whose mental health may be 
negatively affected by being invited to participate in the trial) and the 
rationale for exclusion will be captured. The response rate among 
invited higher risk intervention participants is expected to be ~30%. 
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3.3. AF risk prediction algorithm 
The AF risk prediction algorithm was developed using machine 
learning techniques and data from a retrospective cohort of 2,994,837 
adult patients (aged ≥30 years) without a history of AF (prior to January 
2006) and listed on the CPRD GOLD between January 2006 and 
December 2016 [18]. During the study period, 3.2% of the cohort were 
diagnosed with AF. Both baseline (patient demographics (age, sex, race, 
smoking status), history of antihypertensive use, type 1 or type 2 dia-
betes, and cardiovascular comorbidities) and time-varying (recent car-
diovascular event(s), recent BMI and change in BMI, recent pulse 
pressure, change in SBP and DBP, and recent frequency of SBP, DBP, and 
BMI recordings) patient data were incorporated into the machine 
learning algorithm to generate a risk score for AF, with the three most 
important predictors of AF found to be recent heart failure, coronary 
heart disease, and myocardial infarction [18] (Supplementary Fig. S1). 
The algorithm was calibrated [19] during development, using cross- 
validation to prevent overfitting and random sampling to define 
training and holdout sets, ensuring the final set was broadly represen-
tative of what the model was trained on. The risk prediction algorithm 
will be run on data from all eligible patients with a valid index date 
following randomisation, and a risk score will be generated for each 
individual. A risk score of ≥7.4% was chosen as the threshold needed for 
the AF risk prediction algorithm as this corresponded to a sensitivity of 
50% (Supplementary Table S1), as assumed in the sample size 
calculations. 
3.4. Intervention group 
Intervention group participants with a risk score ≥ 7.4% and suitable 
for participation in the study will be invited to attend a research clinic 
for diagnostic testing. Following informed consent, participant charac-
teristics and clinical history will be recorded by the research nurse, and a 
12‑lead ECG performed. Intervention arm participants not diagnosed 
with AF following the 12‑lead ECG will be provided with a KardiaMobile 
device (AliveCor Inc., California, USA), if they have access to a 
compatible smartphone or tablet. Those without access to a compatible 
smartphone or tablet will be offered a loan smartphone to use alongside 
the KardiaMobile for the study period and, if declined, will be invited for 
up to two further 12‑lead ECGs. Participants using the KardiaMobile will 
be asked to record their ECG twice daily (morning and evening), in 
addition to any time they feel unwell, for two weeks. Participants will be 
diagnosed with AF by a cardiologist if they have ≥30 s of arrhythmia, 
typical of AF, as per standard guidelines [12,20]. In addition, partici-
pants who are unable to attend the research clinic (e.g. because they are 
housebound or do not have available transport) will be offered a visit at 
home with a portable ECG, followed by the two weeks of KardiaMobile 
monitoring described above. All intervention arm participants with a 
cardiologist-confirmed diagnosis of AF (either from the 12‑lead ECG or 
KardiaMobile data) will have met the primary endpoint for the study 
and will be evaluated for anticoagulation therapy as per local proced-
ures. Intervention arm participants may also be diagnosed with AF 
through routine clinical practice. In addition, participants diagnosed 
with other cardiac abnormalities will also be referred and treated ac-
cording to local policies. 
3.5. Control group 
Control arm participants will have no direct contact with in-
vestigators during the study. Control arm participants will only be 
diagnosed with AF through routine clinical practice, and any diagnoses 
will be made according to local policies. 
3.6. Statistical methods 
3.6.1. Sample size 
Owing to the pragmatic design of the trial, the recruitment of six 
study sites will result in an estimated 24,000 patients who meet the 
inclusion criteria. Based on data from the AF risk prediction algorithm 
development [18], it is assumed that approximately 1000 patients per 
arm will be at higher risk of AF (risk score ≥ 7.4%). Of these 1000 
intervention arm participants, it is estimated that: ~30% will accept the 
invitation to attend the research clinic (see Supplementary Fig. S2 for a 
summary of estimated patient and participant numbers in each cohort of 
the trial); 1 in 16 of those who attend the clinic will be diagnosed with 
AF; and – over a six month period – 0.7% of those who do not attend the 
research clinic will be diagnosed with AF [18]. Thus, assuming an AF 
diagnosis rate of 2.4% in higher risk patients in the intervention arm and 
0.7% in the control arm, and a 5% Type-I error rate, this yields a sta-
tistical power for the study of 88.5%. Power calculations were con-
ducted using the ‘pow’ package in R version 3.4.2. 
3.6.2. Statistical analysis 
Demographics and clinical characteristics for all randomised par-
ticipants, and for the primary analysis group of higher risk participants 
(risk score of ≥7.4%), will be summarised using descriptive statistics. If 
the baseline characteristics of the intervention and control arms are well 
balanced, the proportion of patients diagnosed with AF during the 
research window will be compared between the intervention and control 
Table 1 
A schedule for enrolment, intervention and assessment according to the Stan-
dard Protocol Items: Recommendations for Interventional Trials (SPIRIT) 
indications.  
Timepoint Study period 
Enrolment Allocation Post-allocation 
Research 
clinic 
Two 
weeks 
post- 
research 
clinic 
Three- 
year 
follow- 
up 
− T1 T0 T1 T2 T3 
Enrolment 
Eligibility 
determination 
X     
Assessment of 
AF risk 
X     
Treatment 
allocation  
X    
Informed 
consent   
X    
Interventions 
12-lead ECG (or 
6-lead for 
housebound 
participants)   
X Xa  
KardiaMobile   X X   
Assessments 
Baseline patient 
characteristics 
and medical 
history   
X   
Diagnosis of AF   X X Xb 
AF: atrial fibrillation; ECG: electrocardiogram. 
− T1: activities prior to randomisation/treatment allocation, including deter-
mination of patient eligibility from medical records and generation of an AF risk 
score; T0: randomisation/treatment allocation; T1: research clinic appointment; 
T2 completion of KardiaMobile monitoring period; T3: follow-up to assess the 
number of AF diagnoses in intervention arm participants beyond the research 
window. 
a If unsuitable for KardiaMobile monitoring (i.e. without access to a compat-
ible smartphone/tablet). 
b Data on related events (e.g. stroke, mortality etc.) may be collected along-
side AF diagnoses. 
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Fig. 1. PULsE-AI Trial flow chart according to CONsolidated Standards of Reporting Trials. 
AF: atrial fibrillation, ECG: electrocardiogram, EMIS: Egton Medical Information Systems, GP: general practitioner. 
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arms via an unadjusted chi-squared comparison. Alternately, if there are 
baseline differences between arms, these will be adjusted for within a 
penalised logistic regression. A sensitivity analysis will also be per-
formed on all participants randomised into intervention and control 
groups irrespective of predicted AF risk score. All statistical tests will be 
conducted at the 5% significance level. 
The primary outcome will be utilised to inform an economic analysis 
designed to evaluate the health economic impact of a screening strategy 
using the AF risk prediction algorithm (combined with a diagnostic test 
(s)) for the identification of patients with undiagnosed AF (secondary 
objective). The cost-effectiveness model will compare the use of the AF 
risk prediction algorithm intervention as an add-on to current practice 
against current practice alone. The model will use AF incidence rates 
determined from this trial alongside data from published literature (for 
variables such as AF-related event rates and cost estimates) to evaluate 
outcomes over a patient’s lifetime. The economic value of the AF risk 
prediction algorithm will be captured through the estimation of total 
costs, life years gained as a result of earlier diagnosis of AF, and quality- 
adjusted life years gained as a result of avoiding AF-related events due to 
earlier diagnosis. 
3.6.3. Data management 
In line with ethical approval requirements, pseudonymised patient- 
level data from participating study sites will be extracted from the 
Egton Medical Information System (EMIS) medical records of all eligible 
patients via a search and report function. Eligible patients without a 
valid index date will be excluded prior to the randomisation of patients 
at each study site. Following randomisation, data will be used to 
generate AF risk scores for all participants in the intervention and con-
trol arms, and those at highest risk of AF (risk score ≥ 7.4%) identified. 
Study sites will then de-anonymise records of the highest risk patients in 
the intervention arm for invitation. Once participants have signed 
informed consent, data collected during and after the research clinic 
appointment will be entered into the EMIS electronic medical records for 
each participant. All ECG data will be pseudonymised for cardiologist 
review. All KardiaMobile data will be uploaded to secure European 
Servers based on unique study identifiers. Pseudonymised data will be 
shared with the trial sponsor (and its delegates) using secure file transfer 
protocol (sFTP), which will ensure an end to end encryption of data 
extracted. Three years of additional follow-up data may be collected 
from the medical records of participants identified as higher risk by the 
AF risk prediction algorithm to evaluate the impact of the intervention 
on clinical outcomes, but will not involve direct patient contact. Consent 
for all pseudonymised data sharing outside of that collected at the 
research clinic has been provided by the general practice participating in 
the study. 
3.7. Ethical approval and trial registration 
Ethical approval for this study was granted on 28 February 2019 
(Wales Research Ethics Committee 5 - Bangor). Health Research Au-
thority (HRA) and Health and Care Research Wales (HCRW) approval 
for the study were granted on 09 April 2019. The trial was registered 
with clinicaltrials.gov (NCT04045639) on 05 August 2019. This manu-
script is aligned with version 3 of the protocol; substantial protocol 
amendments were approved on 12 December 2019 and 08 February 
2020. 
4. Discussion 
The PULsE-AI trial is designed to assess the performance of a ma-
chine learning AF risk prediction algorithm alongside diagnostic testing 
(12‑lead ECG ± KardiaMobile) at identifying and detecting patients with 
undiagnosed AF, and thus evaluate a complete screening strategy that 
could be applied in a current UK primary care setting. Whilst the AF risk 
prediction algorithm assessed in this study has been shown to reduce the 
potential number of patients needed to screen to detect undiagnosed AF 
by 31% [18] following theoretical validation, whether it is similarly 
effective at identifying patients at higher risk of AF within a real-world 
primary care setting is currently unknown. 
Current AF screening approaches are limited by either cost- 
effectiveness or diagnostic precision [8,12]. Emerging technologies 
such as the KardiaMobile monitor and smartwatches are now widely 
available and increase the accessibility of home-based ECG recording; 
however, they can be expensive and may be technologically prohibitive 
to older patient populations who are at higher risk of AF. Indeed, the 
recent Apple Heart Study [21] invited people with access to a smart-
watch to participate in a study. The study sought to measure the pro-
portion of participants with an irregular pulse notification – and confirm 
AF or atrial flutter with an ECG. However, this study was skewed in 
favour of young to middle age adults who were most likely to have the 
technology, reducing the applicability of findings to older populations at 
highest risk of AF. 
Machine learning techniques appear to be effective in the identifi-
cation of undiagnosed AF [22–24], however all known studies involved 
the application of machine learning algorithms to ECG data. The novelty 
of this study is that the AF risk prediction algorithm does not require 
ECG data as an input and utilises routinely collected data contained 
within existing medical records. If successful, this approach which does 
not rely on existing ECG data or on patient access to emerging tech-
nologies could be of significant value to patients, clinicians, and budget- 
constrained healthcare systems alike. 
The success of the study depends on several factors. First, the as-
sumptions made during the sample size and power analysis calculations 
are correct. Calculations have been made based on observations from 
the AF risk prediction algorithm study [18], and yield a statistical power 
of 88%. Any changes in these assumptions could potentially affect the 
number of AF diagnoses made during the research window and therefore 
the primary outcome. Second, all calculations were made based on the 
population distribution as per the CPRD GOLD dataset used to develop 
the risk prediction algorithm. Therefore, if local populations vary 
significantly from the CPRD GOLD dataset (e.g. they are younger), more 
practices may need to be recruited to reach a sample size of approxi-
mately 1000 higher risk participants per arm. Third, AF will be diag-
nosed during the study via 12‑lead ECG or the KardiaMobile device. 
Whilst participants without a personal smartphone or tablet (or access to 
a device via a family member) will be offered a loan smartphone for the 
KardiaMobile monitoring period, some may lack confidence with tech-
nology and either decline the offer or are unable to use it correctly. 
Although these participants will be invited for subsequent 12‑lead ECGs, 
the absence of home-based ECG monitoring may reduce the ability to 
confirm the actual presence or absence of AF. 
4.1. Limitations 
This trial will be subject to several limitations. As with all multi-
centre studies, the generalisability of trial findings to patients/settings 
beyond the participating practices and surrounding areas is uncertain. 
Therefore, generalisations will be made with caution and both known 
and unknown differences in the study population that may impact the 
applicability of the trial will be discussed. 
Due to the nature of the trial, patients may be ‘flagged’ as high risk of 
AF by the algorithm but are not subsequently diagnosed with AF. 
However, given the often-intermittent nature of AF, and/or the absence 
of a compatible smartphone in some participants, it will not be possible 
to confirm a genuine absence of AF in this subset of patients. Further-
more, it is possible that patients identified by the algorithm as higher- 
risk may have been picked up later by routine methods (lead-time 
bias). However, as both the intervention arm and the control arm have 
the same chance to identify AF patients opportunistically, we should be 
able to quantify this bias. 
Due to the individually randomised design, both intervention and 
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control participants will be present at study sites. It is, therefore, 
possible that physicians may increase their efforts to diagnose patients 
beyond what would be considered routine care as a result of being 
involved in an AF study (performance bias). To ensure the control arm 
closely reflected routine clinical care, we only recruited practices that 
were not active in cardiovascular-related research at the time of trial site 
recruitment. Practices were not restricted from participating in any 
local, regional or national AF detection initiatives during the course of 
the trial. 
Every effort will be made to ensure that patients in the control arm 
and patients in the intervention arm will receive routine care as is 
usually delivered in clinical practice through appropriate training of 
practice researchers. Additionally, participants will be informed not to 
allow family or friends to use their KardiaMobile device as it could 
artificially inflate the number of diagnoses in either the control or 
intervention arms. 
Finally, the COVID-19 pandemic may impact on trial recruitment 
because of the suspension of all non-essential services in primary care in 
England. Whether this will have an impact on the trial beyond simply 
extending the trial period is currently unknown. 
5. Conclusion 
Timely diagnosis of AF and optimal anticoagulation therapy (where 
required) can reduce the risk of AF-related events such as stroke. If the 
PULsE-AI trial is successful, the algorithm could become a valuable 
diagnostic adjunct, implementable in primary care for narrowing the 
population considered at highest risk of AF who should undergo more 
intensive testing (e.g. with a 12‑lead ECG), and therefore enable a more 
cost-effective strategy of screening for undiagnosed AF. 
6. Trial status 
Currently, six general practices are enrolled in the study. Patients at 
these practices have been randomised, and those at highest risk of AF 
identified. The first participant attended the research clinic in August 
2019. Recruitment was placed on hold on 16 March 2020 due to the 
COVID-19 pandemic. The trial restarted on 21 July 2020, with some 
modifications (e.g. the provision of home visits) to minimise the risks to 
participants and the research team whilst operating within local and 
national guidelines. 
Ethics approval and consent to participate 
This study will be performed in accordance with the Declaration of 
Helsinki. Ethical approval has been obtained from the NHS Health 
Research Authority and Health and Care Research Wales (HCRW) (IRAS 
project ID: 252934). The trial has been registered with clinicaltrials.gov 
(NCT04045639). 
Participating General Practices have already provided consent on 
behalf of their patients for pseudonymised data to be used for research. 
Informed consent will be obtained for all participants randomised to the 
intervention group who accept the invitation for diagnostic testing 
before the collection of any data from the research clinic appointment. 
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